Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Saskatchewan

$17,500.00

Validating neurodegenerative mechanisms of RNA binding protein dysfunction in multiple sclerosis

FY 2022-23

Summary
Canada has one of the highest rates of multiple sclerosis (MS), an autoimmune disease of the brain and spinal cord, in the world. In MS, the immune system attacks myelin, the protective covering on nerve cells, and causes symptoms that can sometimes be managed with current MS therapies. Worsening of the disease over time (also known as disease progression) is caused by neurodegeneration, the damage and loss of nerve cells. There are no treatments for neurodegeneration in MS because the cause is still unknown. A protein called heterogeneous nuclear ribonucleoprotein A1 (A1) plays an important role in nerve cell survival, however, A1 malfunctions in MS and thus, may contribute to neurodegeneration. Malfunction of proteins like A1 is common in other neurologic diseases and can lead to the formation of protein aggregates, or clumps, that can damage nerve cells. This project will evaluate whether A1 malfunction in nerve cells is associated with markers of neurodegeneration in MS, including nerve cell death and inflammation. To investigate how A1 malfunction damages nerve cells, I will analyze nerve cells with A1 malfunction for signs of damage, including protein aggregate formation. Understanding what causes neurodegeneration in MS is the first step towards developing effective treatments that prevent disease progression. Since therapies already exist for diseases with malfunction of proteins like A1, verifying that A1 malfunction contributes to neurodegeneration in MS may expand the therapeutic options available for people living with MS.
Program
Master's Award: Canada Graduate Scholarships
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
485942
Name
Messmer Miranda L
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Validating neurodegenerative mechanisms of RNA binding protein dysfunction in multiple sclerosis
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autophagy; Demyelination; Experimental Autoimmune Encephalomyelitis; Hnrnp A1; Inflammation; Multiple Sclerosis; Neurodegeneration; Neuropathology; Oxidative Stress; Rna Binding Protein
Abstract
Canada has one of the highest rates of multiple sclerosis (MS), an autoimmune disease of the brain and spinal cord, in the world. In MS, the immune system attacks myelin, the protective covering on nerve cells, and causes symptoms that can sometimes be managed with current MS therapies. Worsening of the disease over time (also known as disease progression) is caused by neurodegeneration, the damage and loss of nerve cells. There are no treatments for neurodegeneration in MS because the cause is still unknown. A protein called heterogeneous nuclear ribonucleoprotein A1 (A1) plays an important role in nerve cell survival, however, A1 malfunctions in MS and thus, may contribute to neurodegeneration. Malfunction of proteins like A1 is common in other neurologic diseases and can lead to the formation of protein aggregates, or clumps, that can damage nerve cells. This project will evaluate whether A1 malfunction in nerve cells is associated with markers of neurodegeneration in MS, including nerve cell death and inflammation. To investigate how A1 malfunction damages nerve cells, I will analyze nerve cells with A1 malfunction for signs of damage, including protein aggregate formation. Understanding what causes neurodegeneration in MS is the first step towards developing effective treatments that prevent disease progression. Since therapies already exist for diseases with malfunction of proteins like A1, verifying that A1 malfunction contributes to neurodegeneration in MS may expand the therapeutic options available for people living with MS.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Messmer, Miranda L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~
University of Saskatchewan - $17,500 Grant (2022-23) | Canada Spends